HWAM
RCKT icon

Hennion & Walsh Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Hennion & Walsh Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$769K Sell
224,927
-62,888
-22% -$209K 0.02% 638
2026
Q1 		$1.03M Sell
287,815
-21,432
-7% -$85.2K 0.03% 503
2025
Q4 		$1.09M Buy
309,247
+3,809
+1% +$13K 0.04% 495
2025
Q3 		$996K Buy
305,438
+31,179
+11% +$98.2K 0.04% 510
2025
Q2 		$672K Buy
274,259
+24,733
+10% +$125K 0.03% 589
2025
Q1 		$1.66M Buy
249,526
+12,027
+5% +$119K 0.07% 324
2024
Q4 		$2.99M Buy
237,499
+16,453
+7% +$248K 0.14% 190
2024
Q3 		$4.08M Buy
221,046
+16,936
+8% +$347K 0.19% 129
2024
Q2 		$4.39M Sell
204,110
-27,177
-12% -$624K 0.23% 98
2024
Q1 		$6.23M Buy
231,287
+37,937
+20% +$1.08M 0.33% 52
2023
Q4 		$5.79M Buy
193,350
+42,276
+28% +$933K 0.33% 60
2023
Q3 		$3.1M Buy
151,074
+25,845
+21% +$470K 0.2% 126
2023
Q2 		$2.49M Buy
125,229
+21,597
+21% +$436K 0.15% 184
2023
Q1 		$1.77M Buy
103,632
+4,641
+5% +$90.9K 0.11% 230
2022
Q4 		$1.94M Buy
98,991
+40,919
+70% +$754K 0.12% 215
2022
Q3 		$927K Buy
58,072
+14,460
+33% +$226K 0.06% 344
2022
Q2 		$600K Buy
+43,612
New +$520K 0.04% 449

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Hennion & Walsh Asset Management's RCKT Position: Q2 2026 in Review

Hennion & Walsh Asset Management reduced its Rocket Pharmaceuticals (RCKT) stake by 22% in Q2 2026, selling an estimated $209K and leaving 224,927 shares worth $769K. The position accounts for 0.02% of the portfolio, ranked #638.

Hennion & Walsh Asset Management first reported a position in RCKT in Q2 2022 and has held it in 17 quarters since. The position peaked at $6.23M in Q1 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Hennion & Walsh Asset Management held 224,927 shares of Rocket Pharmaceuticals worth $769K as of Q2 2026.
  • Hennion & Walsh Asset Management sold 62,888 Rocket Pharmaceuticals shares in Q2 2026, an estimated $209K.
  • Rocket Pharmaceuticals made up 0.02% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #638 holding.
  • Hennion & Walsh Asset Management first reported a position in Rocket Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Hennion & Walsh Asset Management's Rocket Pharmaceuticals position peaked at $6.23M in Q1 2024.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.